PER
$5M—
Percheron Therapeutics
Biotech · Oncology
ATR inhibitor PRCH-1 for solid tumours, in-licensed from Merck KGaA
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$5M
Burn Rate
—
Shares Outstanding
1.3B
Pipeline Assets
1
Latest Insight(1)
15 Apr 2026Insider TradeChange of Director's Interest Notice
2 transactions·+$107k net buyGarner: bought $107k
3M Price
PER.ASX$0.004-50.0% 3M
Low $0.004High $0.009
Pipeline Assets (1)
PRCH-1Solid tumours (ATR inhibitor)
Phase 1Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
PRCH-1
Solid tumours (ATR inhibitor)
Capital Raises & Buybacks
4 raises
Current shares outstanding: 1.3B
Rights Issue
2026-04-14rights issue
$2.2M
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
6 competitor trialsPhase 2+ · Non-ASX
Solid Tumours (Atr Inhibitor)6 active trials
1 Ph25 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 1 upcoming · 3 past
HMBD-002 preclinical data at ASCO 2026
UpcomingConfirmedremoveMed30 May 2026
expand_more3 past catalysts
ConfirmedremoveMed30 Mar 2026
New preclinical data for HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator VISTA, has been accepted for presentation at ASCO 2026. The data is the result of an ongoing research collaboration between Percheron and QIMR Berghofer focused on exploring VISTA's role in several cancer types and identifying potential biomarkers for future clinical trials. Full results will be shared at the time of the conference in accordance with ASCO embargo policies.
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials